RxDoctor Payments Data

Edwin Chan, MD

Family Medicine · Palm Bay, FLNPI 1124142054

Payments from drug & device makers

$2,543in general payments, 2019–2025

Across 109 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$512
  • Johnson & Johnson$442
  • Novo Nordisk$440
  • AbbVie$254
  • Lilly USA, LLC$189
  • Phathom Pharmaceuticals, Inc.$178
  • plus $528 from 17 others

What the payments were for

  • Food & beverage$2,543100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,543 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$627,980
Medicare patients
878
Services billed
11,988

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$185,664
EliquisApixaban94$75,699
MounjaroTirzepatide65$69,741
JardianceEmpagliflozin64$60,725
FarxigaDapagliflozin Propanediol34$38,648
Trelegy ElliptaFluticasone/Umeclidin/Vilanter38$36,686
Repatha SureclickEvolocumab27$34,519
RybelsusSemaglutide14$32,866
ProliaDenosumab17$28,459
LinzessLinaclotide22$21,454
XareltoRivaroxaban23$20,224
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$16,737
GlyxambiEmpagliflozin/Linagliptin13$10,732
Breo ElliptaFluticasone/Vilanterol19$9,789
Synjardy XrEmpagliflozin/Metformin Hcl11$9,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$440$218,530143 claims
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr$17$81,20988 claims
PfizerEliquis$96$75,69994 claims
Lilly USA, LLCMounjaro$189$69,74165 claims
AstraZenecaFarxiga, Breztri Aerosphere$17$55,38559 claims
GSKTrelegy Ellipta, Breo Ellipta$512$46,47457 claims
AbbVieLinzess$254$21,45422 claims
Johnson & JohnsonXarelto$442$20,22423 claims
Astellas Pharma US IncMyrbetriq$27$8,97119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Palm Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →